Introgen Therapeutics , Inc.

Introgen Therapeutics, Inc., a mature, privately held biotechnology company, is a world leader in the development of gene-based therapeutics. Introgen's lead product, RPR/INGN 201, is being developed in collaboration with Rhône-Poulenc Rorer. With a successful track record of gene therapy product development, the Company has treated hundreds of cancer patients with thousands of doses in clinical trials being conducted throughout the world. Introgen controls a broad intellectual property portfolio that includes more than 130 pending and issued patents for a variety of gene therapy technologies and delivery systems. The Company has active collaborations with numerous academic centers of excellence and pharmaceutical and biotechnology industry ( www.introgen.com )